Cannabinoid administration increases 5HT1A receptor binding and mRNA expression in the hippocampus of adult but not adolescent rats

Neuroscience

Volumn 169, Issue 1, 2010, Pages 315-324

  Zavitsanou, K ^a,b   Wang, H ^a   Dalton, V S ^a,b   Nguyen, V ^a  

^a AUSTRALIAN NUCLEAR SCIENCE AND TECHNOLOGY ORGANISATION   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

Author keywords

Adolescence; Cannabinoid; Hippocampus; HU210; Serotonin receptors

Indexed keywords

DEXANABINOL; MESSENGER RNA; SEROTONIN 1A RECEPTOR;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANNABIS ADDICTION; COGNITIVE DEFECT; CONTROLLED STUDY; DENTATE GYRUS; HIPPOCAMPUS; LIMBIC CORTEX; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR BINDING; RECEPTOR DENSITY;

AGE FACTORS; ANIMALS; DENTATE GYRUS; DRUG ADMINISTRATION SCHEDULE; GYRUS CINGULI; HIPPOCAMPUS; MALE; RATS; RATS, WISTAR; RECEPTOR, SEROTONIN, 5-HT1A; RNA, MESSENGER; SEPTAL NUCLEI; SEROTONIN; SOMATOSENSORY CORTEX; TETRAHYDROCANNABINOL;

EID: 77953807329     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.04.005     Document Type: Article

References (43)

1. Abdel-Fattah A.F., Matsumoto K., el-Hady K.A., Watanabe H. 5-HT1A and 5-HT2 receptors mediate hypo- and hyperthermic effects of tryptophan in pargyline-pretreated rats. Pharmacol Biochem Behav 1995, 52:379-384.
2. Andersen S.L. Trajectories of brain development: point of vulnerability or window of opportunity?. Neurosci Biobehav Rev 2003, 27:3-18.
3. Barnes N.M., Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999, 38:1083-1152.
4. Caberlotto L., Rimondini R., Hansson A., Eriksson S., Heilig M. Corticotropin-releasing hormone (CRH) mRNA expression in rat central amygdala in cannabinoid tolerance and withdrawal: evidence for an allostatic shift?. Neuropsychopharmacology 2004, 29:15-22.
5. Chaperon F., Thiebot M.H. Behavioral effects of cannabinoid agents in animals. Crit Rev Neurobiol 1999, 13:243-281.
6. Cheetham S.C., Crompton M.R., Katona C.L., Horton R.W. Brain 5-HT1 binding sites in depressed suicides. Psychopharmacology (Berl) 1990, 102:544-548.
7. Dalton V.S., Wang H., Zavitsanou K. HU210-induced downregulation in cannabinoid CB1 receptor binding strongly correlates with body weight loss in the adult rat. Neurochem Res 2009, 34:1343-1353.
8. Dalton V.S., Zavitsanou K. Cannabinoid effects on CB1 receptor density in the adolescent brain: an autoradiographic study using the synthetic cannabinoid HU210. Synapse 2010, 10.1002/Syn.20801.
9. Darmani N.A., Janoyan J.J., Kumar N., Crim J.L. Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover. Pharmacol Biochem Behav 2003, 75:777-787.
10. Depue R.A., Spoont M.R. Conceptualizing a serotonin trait. A behavioral dimension of constraint. Ann N Y Acad Sci 1986, 487:47-62.
11. Devlin M.G., Christopoulos A. Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum. J Neurochem 2002, 80:1095-1102.
12. Egashira N., Mishima K., Katsurabayashi S., Yoshitake T., Matsumoto Y., Ishida J., Yamaguchi M., Iwasaki K., Fujiwara M. Involvement of 5-hydroxytryptamine neuronal system in Delta(9)-tetrahydrocannabinol-induced impairment of spatial memory. Eur J Pharmacol 2002, 445:221-229.
13. Eison A.S., Eison M.S. Serotonergic mechanisms in anxiety. Prog Neuropsychopharmacol Biol Psychiatry 1994, 18:47-62.
14. Ferrari F., Ottani A., Vivoli R., Giuliani D. Learning impairment produced in rats by the cannabinoid agonist HU 210 in a water-maze task. Pharmacol Biochem Behav 1999, 64:555-561.
15. Freund T.F., Katona I., Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 2003, 83:1017-1066.
16. Giuliani D., Ferrari F., Ottani A. The cannabinoid agonist Hu 210 modifies rat behavioural responses to novelty and stress. Pharmacol Res 2000, 41:45-51.
17. Hampson R.E., Deadwyler S.A. Role of cannabinoid receptors in memory storage. Neurobiol Dis 1998, 5:474-482.
18. Hermann H., Marsicano G., Lutz B. Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 2002, 109:451-460.
19. Hill M.N., Froc D.J., Fox C.J., Gorzalka B.B., Christie B.R. Prolonged cannabinoid treatment results in spatial working memory deficits and impaired long-term potentiation in the CA1 region of the hippocampus in vivo. Eur J Neurosci 2004, 20:859-863.
20. Howlett A.C., Breivogel C.S., Childers S.R., Deadwyler S.A., Hampson R.E., Porrino L.J. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004, 47(Suppl 1):345-358.
21. Hoyer D., Clarke D.E., Fozard J.R., Hartig P.R., Martin G.R., Mylecharane E.J., Saxena P.R., Humphrey P.P. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (Serotonin). Pharmacol Rev 1994, 46:157-203.
22. Lawston J., Borella A., Robinson J.K., Whitaker-Azmitia P.M. Changes in hippocampal morphology following chronic treatment with the synthetic cannabinoid WIN 55,212-2. Brain Res 2000, 877:407-410.
23. Mato S., Aso E., Castro E., Martin M., Valverde O., Maldonado R., Pazos A. CB1 knockout mice display impaired functionality of 5-HT1A and 5-HT2A/C receptors. J Neurochem 2007, 103:2111-2120.
24. Moore T.H., Zammit S., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 2007, 370:319-328.
25. Moranta D., Esteban S., Garcia-Sevilla J.A. Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain. Naunyn Schmiedebergs Arch Pharmacol 2004, 369:516-524.
26. Morrish A.C., Hill M.N., Riebe C.J., Gorzalka B.B. Protracted cannabinoid administration elicits antidepressant behavioral responses in rats: role of gender and noradrenergic transmission. Physiol Behav 2009, 98:118-124.
27. Murray R.M., Morrison P.D., Henquet C., Di Forti M. Cannabis, the mind and society: the hash realities. Nat Rev Neurosci 2007, 8:885-895.
28. Nakazi M., Bauer U., Nickel T., Kathmann M., Schlicker E. Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors. Naunyn Schmiedebergs Arch Pharmacol 2000, 361:19-24.
29. Ogren S.O., Eriksson T.M., Elvander-Tottie E., D'Addario C., Ekstrom J.C., Svenningsson P., Meister B., Kehr J., Stiedl O. The role of 5-HT(1A) receptors in learning and memory. Behav Brain Res 2008, 195:54-77.
30. Ottani A., Giuliani D. Hu 210: a potent tool for investigations of the cannabinoid system. CNS Drug Rev 2001, 7:131-145.
31. Pacher P., Batkai S., Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58:389-462.
32. Patton G.C., Coffey C., Carlin J.B., Degenhardt L., Lynskey M., Hall W. Cannabis use and mental health in young people: cohort study. BMJ 2002, 325:1195-1198.
33. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Academic Press, Sydney.
34. Pertwee R.G. Ligands that target cannabinoid receptors in the brain: from THC to anandamide and beyond. Addict Biol 2008, 13:147-159.
35. Rubino T., Parolaro D. Long lasting consequences of cannabis exposure in adolescence. Mol Cell Endocrinol 2008, 286:S108-S113.
36. Russo E.B. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers 2007, 4:1614-1648.
37. Santucci A.C., Knott P.J., Haroutunian V. Excessive serotonin release, not depletion, leads to memory impairments in rats. Eur J Pharmacol 1996, 295:7-17.
38. Simansky K.J. Serotonergic control of the organization of feeding and satiety. Behav Brain Res 1996, 73:37-42.
39. Spear L.P. The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev 2000, 24:417-463.
40. Tagliaferro P., Javier Ramos A., Onaivi E.S., Evrard S.G., Lujilde J., Brusco A. Neuronal cytoskeleton and synaptic densities are altered after a chronic treatment with the cannabinoid receptor agonist WIN 55,212-2. Brain Res 2006, 1085:163-176.
41. Tzavara E.T., Davis R.J., Perry K.W., Li X., Salhoff C., Bymaster F.P., Witkin J.M., Nomikos G.G. The CB1 receptor antagonist SR 141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br J Pharmacol 2003, 138:544-553.
42. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science 2002, 296:678-682.
43. Zavitsanou K., Huang X.F. Decreased [(3)H] spiperone binding in the anterior cingulate cortex of schizophrenia patients: an autoradiographic study. Neuroscience 2002, 109:709-716.